

From: Prof. Khosrow Adeli – IFCC President
Date: May 21th, 2021
Ref: New IFCC Taskforce on Outcome Studies in Laboratory Medicine (TF-OSLM)

PRESIDENT

Prof. Khosrow ADELI
Pediatric Laboratory Medicine
The Hospital for Sick Children
University of Toronto
Ontario M5G 1X8 - Canada
Email: president@ifcc.org

SECRETARY

Dr. David KINNIBURGH
Alberta Centre for Toxicology
University of Calgary
Alberta T2N 4N1 – Canada
Email: dkinnibu@ucalgary.ca

TREASURER

Prof. Alexander HALIASSOS
ESEAP - Greek Proficiency Testing Scheme
for Clinical Laboratories
GSCC-CB
GR-106 76 Athens - Greece
Email: haliassos@moleculardiagnosics.gr

CORPORATE REPRESENTATIVE

Mr. Joseph PASSARELLI
Scientific Relations, Roche Diagnostic Operations
Centralized and Point of Care Solutions
Research and Development
Indianapolis, IN 46250-0457 - USA
Email: joseph.passarelli@roche.com

**IFCC REGIONAL FEDERATION
REPRESENTATIVES**

African Federation of Clinical Chemistry (AFCC)
Prof. Adekunle Bashiru OKESINA
Department of Chemical Pathology and Immunology -
University of Ilorin
Kwara State – Nigeria
Email: drokesina@yahoo.com

Arab Federation of Clinical Biology (AFCB)
Prof. Abderrazek HEDHILI
Laboratoire de Toxicologie CMYAMU
Montfleury 1008 - Tunisia
Email: abderrazek.hedhili@yahoo.fr

**Asia-Pacific Federation for Clinical Biochemistry and
Laboratory Medicine (APFCB)**
Dr. Sunil SETHI
Department of Laboratory Medicine
National University Hospital
Singapore 119074
Email: patsks@nus.edu.sg

**European Federation of Clinical Chemistry and
Laboratory Medicine (EFLM)**
Prof. Ana-Maria ŠIMUNDIĆ
Head of the Department of Medical Laboratory Diagnostics
University Hospital "Sveti Duh"
10 000 Zagreb - Croatia
Email: am.simundic@gmail.com

**Latin-American Confederation of Clinical Biochemistry
(COLABIOCLI)**
Dr. Ana María LENA RODRÍGUEZ
Clinical Biochemistry Department
University of Uruguay
Montevideo CP 11300 - Uruguay
Email: analena@vera.com.uy

**North American Federation of Clinical Chemistry and
Laboratory Medicine (NAFCC)**
Dr. Stephen HILL
Department of Pathology and Molecular Medicine
McMaster University
Hamilton, Ontario L8N 3Z5, Canada
Email: hillstev@hhsc.ca

IFCC Office
Via Carlo Farini, 81
20159 Milano – Italy
Tel: +39 02 66809912
Email: ifcc@ifcc.org
website: <http://www.ifcc.org/>

**To: IFCC National Representatives, Regional Federations,
Corporate Members**

Dear all,

The valuable contribution of laboratory medicine to healthcare overall is clear to all of us in IFCC, but not widely recognized outside of our profession. In order to educate others about the value of laboratory medicine it is critical that we identify objective evidence to support our claim. The new IFCC Taskforce on Outcome Studies in Laboratory Medicine will work to **promote the Value of Laboratory Medicine by gathering the evidence to demonstrate the critical role of laboratory medicine in clinical decision making and healthcare delivery**. This will be accomplished through collecting existing research demonstrating value and by collaborating and encouraging new research, particularly in areas such as critical care, endocrinology, cardiology, GI/Nutrition, etc. This evidence gathered from around the world will then be shared with IFCC members and can be used to **promote the critical role of laboratory medicine in healthcare to key stakeholders including governments, administrators and other healthcare workers as well as the public at large**

IFCC Taskforce on Outcome Studies in Laboratory Medicine: Scope & Mandate

- Identify existing peer reviewed, high quality publications that demonstrate the value of laboratory medicine in healthcare overall.
- Develop a funded research program for investigators in hospitals located around the world to conduct new retrospective and prospective research with outcomes that assess the value of laboratory medicine in healthcare overall. The taskforce could help centres in setting up studies to properly collect such data (common study protocols and formats) and publish their findings.
- Create a repository/database of publications that is accessible by members of IFCC.
- Working with CPD and the C-PR, the taskforce will develop publications, presentations, webinars and other communications materials to help IFCC members use this data to effectively promote the critical value of laboratory medicine in healthcare to key stakeholders.
- The Taskforce will closely coordinate with other IFCC groups involved in related activities, including CPD, C-VPLM, TF-CM and others, as required.

Membership: The Taskforce will consist of at least a chair and 4 full members. Corporate representatives from interested companies can also be members. Members will provide expertise, plan for the development of the program and direct the ongoing activities. Term of office: 3 years with the possibility of renewal for a second term.

Meeting Arrangements: 1-2 in person meetings per year, where possible, and monthly virtual meetings via Zoom. Meeting frequency can increase when appropriate.

Reporting: The Taskforce will report directly to the IFCC President and Executive Board and submit a progress report quarterly summarizing progress made within that quarter.

IFCC National Societies and corporate members are invited to nominate experts in the field of OSLM to join this important Taskforce.

Please send the following information to Paola Bramati (paola.bramati@ifcc.org) at the IFCC office by **June 30, 2021**.

- A formal letter explaining the nominee's interest in the position and the contribution that we can expect from the candidate,
- Any proposals or ideas for topics the Taskforce should address
- A short CV.

Taskforce members will be selected from nominations received from national societies and corporate members; however, **expertise in the area as demonstrated by high quality publications in the field, and/or in conducting outcome based clinical research is the most important criterion for selection of Taskforce members**. In addition to those selected from nominations received by membership societies, the IFCC may select some Taskforce members from key experts in the field from around the world. Candidates or nominees that have not been selected can apply to become corresponding members of the Taskforce.

We look forward to nominations from national societies around the world and I am convinced that this new Taskforce will successfully strengthen the IFCC's mission towards better healthcare worldwide.

With kind regards,



Prof. Khosrow Adeli
IFCC President